Zacks Investment Research · Oct 23, 2023
Philip Morris' Q3 Earnings Beat Puts ETFs in Focus
Look into ETFs with an exposure in PM, as the tobacco company reports robust Q3 earnings.
TO
BATS · TOKE
Cambria Cannabis ETF
Financial Services · Asset Management
$5.24
Up+$0.05 (+0.96%)
Updated Sep 19, 2026, 11:00 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 14.01M
- P/E ratio
- —
- Dividend yield
- 3.36%
- 52-week range
- $4.06 – $7.33
- Volume
- 61.03K
- Avg. volume
- 127.17K
Price performance
TOKE price history
1M range · 0 trading sessions · Daily adjusted prices
TOKE does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest TOKE news
The latest Smart Investors Daily articles mentioning TOKE.
Stock researchCompany · Overview
TOKE research
Overview
Company profile and research snapshot.
Company profile
Under normal market conditions, at least 80% of the value of the fund’s net assets (plus borrowings for investment purposes) will be invested in Cannabis Companies. The Advisor generally expects to invest in Cannabis Companies across a broad market capitalization spectrum of micro-, small-, and mid-capitalization stocks.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Aug 1, 2023
Rescheduling Cannabis: What Are The Implications For MSOs, Tax Rule 280E, FDA And Pharma?
The potential of rescheduling and removing Tax Rule 280E could boost profits for U.S. businesses. However, Zuanic and Associates' latest report reveals complexities and overlooked consequences. What is the best option for unlocking the cannabis industry's potential: exploring exemptions or legislative change? Rescheduling MMJ: FDA And Pharma Implications Tax Rule 280E poses a considerable obstacle to cannabis companies, forcing them to pay income tax on gross profits and resulting in an astronomical effective tax rate of 70% for many US plant-touching businesses. While the removal of 280E through cannabis rescheduling appears attractive, Z&A cautions against embracing this narrative without considering its potential "Pandora's Box" of consequences. Rescheduling medical marijuana (MMJ) would indeed make it federally legal, but it could also usher in stricter FDA regulations and limit prescription accessibility for doctors. Additionally, it might lead to the entrance of pharmaceutical companies, altering the industry's dynamics significantly. “Moving MMJ to Schedule II or III would make MMJ federally legal with all that implies: FDA regulation, likely tougher for Drs to prescribe, ...Full story available on Benzinga.com
Benzinga · Jul 31, 2023
MSOs And Cannabis Rescheduling: A Safer Bet? Analyst Looks Closer At Pros And Cons
Will the rescheduling of cannabis fuel a boom in cannabis stocks? Analysts from Z&A delve into the pros and cons of MSOs and cannabis rescheduling in their latest equity research report. Re-scheduling Vs. De-scheduling: What Is The Difference? Re-scheduling cannabis refers to the process of changing its current classification within the legal framework while maintaining some level of regulation. De-scheduling cannabis, on the other hand, involves removing it entirely from the list of controlled substances, eliminating all federal restrictions. If a country classifies cannabis as a Schedule I drug, re-scheduling it to Schedule II would mean acknowledging some medicinal value while retaining restrictions. De-scheduling would altogether remove all legal barriers, allowing it to be treated like any other non-controlled substance. Often, ...Full story available on Benzinga.com
MarketWatch · Jun 11, 2022
As FB becomes META, here are 10 creative ticker symbols
For some companies, those letters are key to building a brand identity
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
